Are you ready for the switch?
Taking tamoxifen to treat early breast cancer is a smart decision that you and your doctor can make. And as many women are finding out, switching to AROMASIN® (exemestane tablets) after 2 to 3 years may also be a smart decision. Find out if you might benefit from switching to AROMASIN. Take this quiz and discuss the results with your doctor.
Take this simple quiz:
Ready to ask your doctor about
switching to AROMASIN?
Make the most of your appointment with a
customizable Doctor Discussion Guide.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
